Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium

Epilepsia
Iolanda MazzucchelliEmilio Perucca

Abstract

To determine potential changes in the plasma concentrations of oxcarbazepine (OXC) and its metabolites during pregnancy and puerperium. Five women receiving OXC monotherapy were followed prospectively during pregnancy and the puerperium. Four women were enrolled in the first trimester, and one woman, 2 weeks before delivery. Steady-state concentrations of OXC, its active R-(-)- and S-(+)-monohydroxy derivatives (MHD), and the additional metabolite carbamazepine-10,11-trans-dihydrodiol (DHD) were measured at regular intervals by an enantioselective HPLC assay. RESULTS. In all samples, S-(+)-MHD was the most abundant compound in plasma and accounted almost entirely for the amount of active moiety (defined as the molar sum of OXC, R-(-)-MHD, and S-(+)-MHD) found in the circulation. The dose-normalized concentrations of active moiety decreased markedly during gestation and, in four of the five patients, increased strikingly after delivery. Plasma concentrations of S-(+)-MHD mirrored closely the levels of the active moiety. Plasma concentrations of the parent drug and other metabolites also tended to decrease during pregnancy and to increase after delivery. During treatment with OXC, S-(+)-MHD is by far the most abundant active comp...Continue Reading

References

Jan 1, 1987·Pharmacology & Therapeutics·E Perucca
Oct 24, 2001·Epilepsy Research·A SabersE L Hansen
Jul 24, 2002·Neurology·T A TranR Remmel
Aug 27, 2003·Neurology·Anne SabersTorbjörn Tomson
Sep 10, 2003·Clinical Pharmacokinetics·Theodor W MayBernhard Rambeck
Jul 3, 2004·Epilepsia·Massimo Avoli
Jun 23, 2005·Current Medical Research and Opinion·Georgia Montouris

❮ Previous
Next ❯

Citations

Mar 3, 2009·Journal of Neurology·Torbjörn Tomson, Dina Battino
Jun 20, 2012·Current Treatment Options in Neurology·Kaarkuzhali Babu Krishnamurthy
Nov 8, 2008·Current Opinion in Obstetrics & Gynecology·Cynthia L Harden, Nitin K Sethi
Jan 31, 2009·Epilepsia·Andreas Austgulen WestinEylert Brodtkorb
Oct 13, 2007·BMJ : British Medical Journal·Torbjörn Tomson, Vilho Hiilesmaa
Oct 20, 2006·Clinical Pharmacokinetics·Svein I Johannessen, Torbjörn Tomson
Dec 8, 2007·Drugs·Dina Battino, Torbjörn Tomson
Nov 26, 2008·Clinical Pharmacokinetics·Penny Bring, Mary H H Ensom
May 24, 2014·Neurobiology of Disease·Emilio PeruccaTorbjörn Tomson
Nov 16, 2007·Journal of Clinical Psychopharmacology·Ulrich C LutzMathias Bartels
Aug 1, 2012·Therapeutic Drug Monitoring·Doreen M Matsui
Jun 18, 2009·Current Opinion in Neurology·Anne Sabers, Torbjörn Tomson
Jul 20, 2010·Pharmaceuticals·Matthew D Krasowski
Mar 8, 2007·Expert Review of Neurotherapeutics·Line Sveberg Røste, Erik Taubøll
Jul 13, 2006·Expert Review of Neurotherapeutics·William O Tatum
Jun 14, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Matthew D Krasowski, Gwendolyn A McMillin
May 29, 2008·Expert Review of Neurotherapeutics·Svein I Johannessen, Cecilie Johannessen Landmark
Jan 1, 2008·Expert Review of Clinical Pharmacology·Anne Sabers, Vaiva Petrenaite
Apr 25, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Pamela M Crawford
Nov 9, 2011·Advanced Drug Delivery Reviews·Cecilie Johannessen LandmarkTorbjörn Tomson
Mar 9, 2010·Thérapie·Régis BouquiéUNKNOWN le groupe Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique
Apr 19, 2016·Neurologic Clinics·Naymeé J Vélez-Ruiz, Page B Pennell
Mar 31, 2009·Epilepsy & Behavior : E&B·Anne Sabers
Feb 24, 2009·Epilepsy Research·Vaiva PetrenaiteJacob Hansen-Schwartz
Nov 13, 2007·Epilepsy & Behavior : E&B·Page B PennellEmilio Perucca
Jul 31, 2007·Epilepsy & Behavior : E&B·Joyce A CramerOrrin Devinsky
Nov 10, 2011·Pharmacoepidemiology and Drug Safety·Cecilie Johannessen Landmark, Svein I Johannessen
Jun 9, 2014·Seizure : the Journal of the British Epilepsy Association·Arne Reimers
Sep 11, 2009·Epilepsy Research·Inger OhmanTorbjörn Tomson
Dec 26, 2007·Seizure : the Journal of the British Epilepsy Association·Eylert Brodtkorb, Arne Reimers
Jan 9, 2008·Seizure : the Journal of the British Epilepsy Association·Andreas Austgulen WestinEylert Brodtkorb
Nov 2, 2016·PLoS Medicine·Gali ParienteGideon Koren
Jun 30, 2018·Therapeutic Drug Monitoring·Philip N PatsalosDave J Berry
Feb 15, 2020·Expert Opinion on Drug Metabolism & Toxicology·Cecilie Johannessen LandmarkPhilip N Patsalos
Apr 14, 2020·PM & R : the Journal of Injury, Function, and Rehabilitation·Marc J HeronemusUNKNOWN MOST Study Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.